Compare Stocks: FDMT, SION, COAG, and ZLAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COAG Hemab Therapeutics	$49.66	$36.52	$23.00 ▼ $53.61	$2.32B	N/A	452,634 shs	415,699 shs
FDMT 4D Molecular Therapeutics	$10.75	$10.72	$5.33 ▼ $14.00	$562.01M	2.73	610,402 shs	346,894 shs
SION Sionna Therapeutics	$51.04	$42.35	$17.09 ▼ $54.97	$2.31B	1.32	621,891 shs	746,247 shs
ZLAB Zai Lab	$23.32	$18.75	$15.96 ▼ $36.77	$2.65B	0.78	723,595 shs	2.05 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COAG Hemab Therapeutics	0.00%	+4.44%	+30.58%	+98.64%	+4,965,999,900.00%
FDMT 4D Molecular Therapeutics	0.00%	+5.60%	-12.67%	-0.37%	+90.94%
SION Sionna Therapeutics	0.00%	+8.30%	+12.70%	+11.08%	+188.85%
ZLAB Zai Lab	0.00%	+27.64%	+13.81%	+19.04%	-33.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COAG Hemab Therapeutics	$49.66	$36.52	$23.00 ▼ $53.61	$2.32B	N/A	452,634 shs	415,699 shs
FDMT 4D Molecular Therapeutics	$10.75	$10.72	$5.33 ▼ $14.00	$562.01M	2.73	610,402 shs	346,894 shs
SION Sionna Therapeutics	$51.04	$42.35	$17.09 ▼ $54.97	$2.31B	1.32	621,891 shs	746,247 shs
ZLAB Zai Lab	$23.32	$18.75	$15.96 ▼ $36.77	$2.65B	0.78	723,595 shs	2.05 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COAG Hemab Therapeutics	0.00%	+4.44%	+30.58%	+98.64%	+4,965,999,900.00%
FDMT 4D Molecular Therapeutics	0.00%	+5.60%	-12.67%	-0.37%	+90.94%
SION Sionna Therapeutics	0.00%	+8.30%	+12.70%	+11.08%	+188.85%
ZLAB Zai Lab	0.00%	+27.64%	+13.81%	+19.04%	-33.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COAG Hemab Therapeutics	2.83	Moderate Buy	$48.00	-3.34% Downside
FDMT 4D Molecular Therapeutics	2.80	Moderate Buy	$30.67	185.27% Upside
SION Sionna Therapeutics	2.85	Moderate Buy	$55.00	7.76% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$40.20	72.38% Upside

Current Analyst Ratings Breakdown

Latest FDMT, SION, COAG, and ZLAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	SION Sionna Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $60.00
8/7/2026	ZLAB Zai Lab	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$44.00 ➝ $45.00
8/6/2026	SION Sionna Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$59.00
8/5/2026	SION Sionna Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/31/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$37.00
7/29/2026	ZLAB Zai Lab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/20/2026	FDMT 4D Molecular Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
7/17/2026	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ZLAB Zai Lab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	COAG Hemab Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $47.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	$85.21M	6.60	N/A	N/A	$8.85 per share	1.21
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	$6.88 per share	N/A
ZLAB Zai Lab	$460.16M	5.77	N/A	N/A	$6.39 per share	3.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COAG Hemab Therapeutics	N/A	-$23.98	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.57	N/A	N/A	N/A	-182.34%	-36.83%	-32.55%	8/10/2026 (Estimated)
SION Sionna Therapeutics	-$75.27M	-$2.18	N/A	N/A	N/A	N/A	-32.94%	-31.08%	N/A
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	N/A

Latest FDMT, SION, COAG, and ZLAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	N/A	N/A	N/A	$3.62 million	N/A
8/6/2026	Q2 2026	SION Sionna Therapeutics	-$0.64	-$0.66	-$0.02	-$0.66	N/A	N/A
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
6/30/2026	Q2 2026	ZLAB Zai Lab	N/A	-$0.50	N/A	-$0.50	N/A	$106.31 million
5/21/2026	Q1 2026	COAG Hemab Therapeutics	N/A	-$23.98	N/A	-$23.98	N/A	N/A
5/12/2026	Q1 2026	SION Sionna Therapeutics	-$0.52	-$0.60	-$0.08	-$0.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COAG Hemab Therapeutics	N/A	12.85	12.85
FDMT 4D Molecular Therapeutics	N/A	9.34	9.34
SION Sionna Therapeutics	N/A	20.05	20.05
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COAG Hemab Therapeutics	N/A
FDMT 4D Molecular Therapeutics	99.27%
SION Sionna Therapeutics	N/A
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
COAG Hemab Therapeutics	N/A
FDMT 4D Molecular Therapeutics	7.90%
SION Sionna Therapeutics	5.10%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COAG Hemab Therapeutics	72	46.71 million	N/A	N/A
FDMT 4D Molecular Therapeutics	120	52.28 million	48.15 million	Optionable
SION Sionna Therapeutics	35	45.21 million	42.91 million	N/A
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

FDMT, SION, COAG, and ZLAB Headlines

Recent News About These Companies

Zai Lab (NASDAQ:ZLAB) Stock Price Up 14.5% on Strong Earnings

August 8 at 1:40 AM | americanbankingnews.com

Zai Lab Q2 Earnings Call Highlights

August 7 at 5:03 PM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Issues Earnings Results, Beats Estimates By $0.18 EPS

August 6, 2026 | marketbeat.com

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 6, 2026 | zacks.com

Zai Lab (NASDAQ:ZLAB) Shares Up 14.5% on Strong Earnings

August 6, 2026 | marketbeat.com

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

August 6, 2026 | businesswire.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of “Moderate Buy” from Analysts

August 4, 2026 | defenseworld.netD

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Recommendation of "Moderate Buy" from Analysts

August 4, 2026 | americanbankingnews.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts

August 4, 2026 | marketbeat.com

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

August 3, 2026 | finance.yahoo.com

Zai Lab (ZLAB) Expected to Announce Earnings on Thursday

July 30, 2026 | americanbankingnews.com

Zai Lab (ZLAB) to Post Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

July 22, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) Stock Price Up 7% - Still a Buy?

July 15, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Sees Unusually-High Trading Volume - Should You Buy?

July 13, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 7,026 Shares

July 2, 2026 | insidertrades.com

Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy

June 30, 2026 | finance.yahoo.com

Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $39,529.44 in Stock

June 30, 2026 | insidertrades.com

Zai Lab (NASDAQ:ZLAB) Director William Lis Sells 7,040 Shares of Stock

June 25, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FDMT, SION, COAG, and ZLAB Company Descriptions

Hemab Therapeutics NASDAQ:COAG

$49.66 0.00 (0.00%)

As of 08/7/2026 04:00 PM Eastern

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.

4D Molecular Therapeutics NASDAQ:FDMT

$10.75 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$11.34 +0.59 (+5.48%)

As of 09:25 AM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Sionna Therapeutics NASDAQ:SION

$51.04 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$5.00 -46.04 (-90.21%)

As of 09:27 AM Eastern

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts.

Zai Lab NASDAQ:ZLAB

$23.32 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$22.66 -0.66 (-2.83%)

As of 09:05 AM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FDMT, SION, COAG, and ZLAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FDMT, SION, COAG, and ZLAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FDMT, SION, COAG, and ZLAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FDMT, SION, COAG, and ZLAB Company Descriptions

Hemab Therapeutics NASDAQ:COAG

4D Molecular Therapeutics NASDAQ:FDMT

Sionna Therapeutics NASDAQ:SION

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FDMT, SION, COAG, and ZLAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FDMT, SION, COAG, and ZLAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FDMT, SION, COAG, and ZLAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

FDMT, SION, COAG, and ZLAB Company Descriptions

Hemab Therapeutics NASDAQ:COAG

4D Molecular Therapeutics NASDAQ:FDMT

Sionna Therapeutics NASDAQ:SION

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools